Previous 10 | Next 10 |
–Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio’s financial runway into 2024 –Dosed first patient in Phase 1/2 trial of investigational gene therapy for congenital adrenal hyperplasia (CAH); initial data reado...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q3-2021 13F filings the consensus holdings were updated, 5 stocks were removed and 5 added from the unive...
- If successful, BridgeBio’s investigational gene therapy BBP-631 would be the first therapy for CAH to restore the body’s hormone and steroid balance by enabling people with CAH to make their own cortisol and aldosterone -Initial Phase 1/2 data readout anticip...
Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB PR Newswire ...
- First clinical combination study of BBP-398 and LUMAKRAS set to evaluate safety and preliminary efficacy in solid tumors with the KRAS G12C mutation PALO ALTO, Calif., Jan. 13, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharma...
Shares of commercial-stage biopharmaceutical company BridgeBio Pharma (NASDAQ: BBIO) fell hard recently after it reported a surprising clinical trial failure. The company's highly valued new drug candidate failed to hit the primary endpoint in a pivotal study. Luckily, there are...
Gainers: Insignia Systems (NASDAQ:ISIG) +83%.. Pop Culture (NASDAQ:CPOP) +24%. Regencell Bioscience RGC +20% BridgeBio Pharma BBIO +19%. Gamida Cell (NASDAQ:GMDA) +17%. ADDvantage Technologies (NASDAQ:AEY) +17%. Centogene (NASDAQ:CNTG) +14% Altamira Therapeu...
Gainers: Altamira Therapeutics (NASDAQ:CYTO) +21%, Regencell Bioscience (NASDAQ:RGC) +17%, BridgeBio Pharma BBIO +13%, ImmunityBio (NASDAQ:IBRX) +8%, BiondVax Pharmaceuticals BVXV +8%. Losers: Biofrontera (NASDAQ:BFRI) -21%, Microbot Medical (...
After losing more than a 70% of its share value on Monday, BridgeBio Pharma (NASDAQ:BBIO) has recovered in the pre-market with a rise of 6.7%. Yesterday, the company announced that it failed to achieve the primary endpoint in its late-stage study for acoramidis in transthyretin (TTR) amy...
BridgeBio Pharma (NASDAQ:BBIO) perks up 3% premarket after shedding around 72% during yesterday's intrady session after its late-stage study for acoramidis in transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) did not meet the primary endpoint. Following this news, sever...
News, Short Squeeze, Breakout and More Instantly...
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and...
2024-07-09 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-20 00:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...